Alexander Arkhipov

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826

R. Shapira-Frommer, S. Keefe, K. Tewari, 2023, Journal of Clinical Oncology.

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

B. Monk, M. Gumus, N. Colombo, 2023, Journal of Clinical Oncology.